Patents Represented by Attorney, Agent or Law Firm Timothy E. Torchia
-
Patent number: 6280732Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.Type: GrantFiled: June 7, 1995Date of Patent: August 28, 2001Assignee: Genentech, Inc.Inventors: Ingrid W. Caras, John W. Winslow
-
Patent number: 6037320Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta., NT-4.gamma., and NT-4.DELTA.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.Type: GrantFiled: September 12, 1997Date of Patent: March 14, 2000Assignee: Genentech, Inc.Inventor: Arnon Rosenthal
-
Patent number: 6027927Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobin sequences.Type: GrantFiled: October 1, 1997Date of Patent: February 22, 2000Assignee: Genentech, Inc.Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
-
Patent number: 6025166Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns imnunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.Type: GrantFiled: May 19, 1995Date of Patent: February 15, 2000Assignee: Genentech, Inc.Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
-
Patent number: 6005081Abstract: Methods are provided for large scale purification of neurotrophins, including mature NGF, suitable for clinical use. The methods provide means to separate neurotrophins from various less desirable misprocessed, misfolded, size, glycosylated, or charge forms. Compositions of neurotrophins, including mature NGF, substantially free of these variants are also provided.Type: GrantFiled: November 14, 1997Date of Patent: December 21, 1999Assignee: Genentech, Inc.Inventors: Louis E. Burton, Charles H. Schmelzer, Joanne T. Beck
-
Patent number: 5981480Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.Type: GrantFiled: May 15, 1995Date of Patent: November 9, 1999Assignee: Genentech, Inc.Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
-
Patent number: 5980894Abstract: The invention relates to monoclonal antibodies to human leukemia inhibitory factor. The disclosed monoclonal antibodies are believed to recognize unique epitopes on hLIF and are useful in the treatment of conditions wherein the presence of hLIF causes or contributes to undesirable pathological effects, such as cachexia, dysregulated calcium metabolism, or excessive bone cell proliferation, and in the detection of hLIF, for example, in clinical samples or specimens.Type: GrantFiled: April 10, 1997Date of Patent: November 9, 1999Assignee: Genentech, Inc.Inventor: Kyung Jin Kim
-
Patent number: 5910574Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.Type: GrantFiled: May 31, 1995Date of Patent: June 8, 1999Assignee: Genentech, Inc.Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
-
Patent number: 5877016Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns inmunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.Type: GrantFiled: August 5, 1994Date of Patent: March 2, 1999Assignee: Genentech, Inc.Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
-
Patent number: 5853978Abstract: Diagnostic product and vaccine for Acquired Immuno-deficiency Syndrome (AIDS) and methods for making and using same, wherein viral polypeptide sequences from an AIDS associated retrovirus are expressed directly or as a fusion polypeptide in a prokaryotic or mammalian cell expression host to produce a diagnostic product which specifically binds complementary antibody produced by individuals afflicted with AIDS or a vaccine against AIDS which confers resistance to infection by AIDS associated retrovirus. The reverse transcriptase of an AIDS associated retrovirus is used separately or in a whole cell assay to identify compounds which selectively inhibit retroviral reverse transcriptase.Type: GrantFiled: July 29, 1994Date of Patent: December 29, 1998Assignee: Genentech, Inc.Inventors: Phillip W. Berman, Daniel J. Capon, Laurence A. Lasky
-
Patent number: 5849533Abstract: Methods for making unclipped HIV env proteins are provided. According to the methods, a genetically engineered cell line comprising an nucleic acid sequence encoding an HIV env protein is cultured to produce unclipped HIV env protein, which is recovered from the cell culture.Type: GrantFiled: February 19, 1997Date of Patent: December 15, 1998Assignee: Genetech, Inc.Inventors: Phillip W. Berman, Brian M. Fendly, Timothy J. Gregory, Elorian M. Wurm
-
Patent number: 5844092Abstract: The invention concerns human trkB and trkC receptors and their functional derivatives. The invention further concerns immunoadhesins comprising trk receptor sequences fused to immunoglobulin sequences.Type: GrantFiled: December 20, 1994Date of Patent: December 1, 1998Assignee: Genentech, Inc.Inventors: Leonard G. Presta, David L. Shelton, Roman Urfer
-
Patent number: 5837241Abstract: A leukemia inhibitory factor antagonist, alone or in combination with an endothelin antagonist, may be used for treatment of heart failure. The antagonist(s) are administered in a chronic fashion, in therapeutically effective amounts, to achieve this purpose.Type: GrantFiled: July 26, 1996Date of Patent: November 17, 1998Assignee: Genentech, Inc.Inventors: Napoleone Ferrara, Kathleen King, Elizabeth Luis, Jennie P. Mather, Nicholas F. Paoni
-
Patent number: 5830858Abstract: A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta. and NT-4.gamma.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.Type: GrantFiled: April 19, 1995Date of Patent: November 3, 1998Assignee: Genentech, Inc.Inventor: Arnon Rosenthal
-
Patent number: 5804557Abstract: Methods and compositions for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with a polyol having a molecular weight less than about 70,000 kD.Type: GrantFiled: September 24, 1996Date of Patent: September 8, 1998Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Andrew J. S. Jones
-
Patent number: 5798448Abstract: The present invention provides nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders.Type: GrantFiled: May 15, 1995Date of Patent: August 25, 1998Assignee: Genentech, Inc.Inventors: Ingrid W. Caras, John W. Winslow
-
Patent number: 5759775Abstract: Provided are nucleic acids encoding AL-1 protein, as well as AL-1 protein produced by recombinant DNA methods. Such AL-1 protein is useful in preparing antibodies and in diagnosing and treating various neuronal disorders. The present invention provides methods to preferentially detect or amplify AL-1 nucleic acid in a sample using AL-1 nucleotide sequence probes.Type: GrantFiled: May 15, 1995Date of Patent: June 2, 1998Assignee: Genetech, Inc.Inventors: Ingrid W. Caras, John W. Winslow
-
Patent number: 5753219Abstract: Methods and compositions for excipient stabilization of dry or aqueous polypeptides treated with organic solvents are disclosed, wherein the polypeptide is admixed with a polyol having a molecular weight less than about 70,000 kD.Type: GrantFiled: May 15, 1995Date of Patent: May 19, 1998Assignee: Genentech, Inc.Inventors: Jeffrey L. Cleland, Andrew J. S. Jones
-
Patent number: 5728803Abstract: Pantropic neurotrophic factors which have multiple neurotrophic specificities are provided. The pantropic neurotrophic factors of the present invention are useful in the treatment of neuronal disorders. Nucleic acids and expression vectors encoding the pantropic neurotrophins are also provided.Type: GrantFiled: May 12, 1995Date of Patent: March 17, 1998Assignee: Genentech, Inc.Inventors: Roman Urfer, Leonard G. Presta, John W. Winslow
-
Patent number: 5723585Abstract: Isolated CHF, isolated DNA encoding CHF, recombinant or synthetic methods of preparing CHF, and a method of purifying CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: May 17, 1995Date of Patent: March 3, 1998Assignee: Genentech, Inc.Inventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennica, William Wood